Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer
jRCT2080225287Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in muscle-invasive bladder carcinoma (MIBC) and transitional cell carcinoma of the bladder (TCC) comparing Pembrolizumab + chemoradiotherapy with Placebo + chemoradiotherapy (2 arms). Started Jul 2020; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder carcinoma (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on jRCT2080225287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225287.